Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Author: m.nasser

Working with Innovest has been a great experience for Rawabi Farah. Their professional approach, innovative solutions, and commitm...

Rawabi Farah

Partnering with Innovest has been a game-changer for us at Mais Irrigation. Their professional approach, attention to detail, and ...

Partnering with Innovest has been a game-changer for us at Mais Irrigation. Their professional approach, attention to detail, and ...

Aljazeera Hospital